Literature DB >> 2844987

Evaluation of an enzyme-linked immunosorbent assay that measures rhinovirus-specific antibodies in human sera and nasal secretions.

W S Barclay1, K A Callow, M Sergeant, W al-Nakib.   

Abstract

Rhinovirus-specific antibodies have traditionally been detected by their ability to neutralise the homologous rhinovirus serotype in tissue culture. Recently, however, we have described an enzyme-linked immunosorbent assay that detects rhinovirus-specific antibodies in sera and nasal secretions [Barclay and Al-Nakib, 1987]. Here we describe an evaluation of the ELISA in a study involving 71 adult volunteers inoculated intranasally with human rhinovirus type 2 (HRV-2). Pre- and post-inoculation serum samples and pre-inoculation nasal washings were tested for the presence of HRV-2-specific antibodies by ELISA. Such antibodies were associated with protection against infection when present locally in nasal secretions, but when also present in the serum they were associated with protection against both infection and the development of illness. The antibody concentrations showed strong correlation with each other and with that of antibodies detected by the neutralisation test. Following HRV-2 infection, rises in HRV-2-specific IgA in sera detected by ELISA occurred more frequently than rises in neutralising antibody. These results suggest that the ELISA is a sensitive and reliable indicator of recent infection, as well as a predictor of homologous immune status.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2844987      PMCID: PMC7166658          DOI: 10.1002/jmv.1890250411

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  PREVENTION OF COLDS BY VACCINATION AGAINST A RHINOVIRUS: A REPORT BY THE SCIENTIFIC COMMITTEE ON COMMON COLD VACCINES.

Authors:  D A MITCHISON
Journal:  Br Med J       Date:  1965-05-22

2.  Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection.

Authors:  K A Callow
Journal:  J Hyg (Lond)       Date:  1985-08

3.  Antigenic determinants of infective and inactivated human rhinovirus type 2.

Authors:  K Lonberg-Holm; F H Yin
Journal:  J Virol       Date:  1973-07       Impact factor: 5.103

Review 4.  The common cold: control?

Authors:  R B Couch
Journal:  J Infect Dis       Date:  1984-08       Impact factor: 5.226

5.  Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges.

Authors:  W Al-Nakib; P G Higgins; I Barrow; G Batstone; D A Tyrrell
Journal:  J Antimicrob Chemother       Date:  1987-12       Impact factor: 5.790

6.  An ELISA for the detection of rhinovirus specific antibody in serum and nasal secretion.

Authors:  W S Barclay; W Al-Nakib
Journal:  J Virol Methods       Date:  1987-01       Impact factor: 2.014

  6 in total
  5 in total

Review 1.  Human rhinoviruses.

Authors:  Samantha E Jacobs; Daryl M Lamson; Kirsten St George; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

2.  The time course of the immune response to experimental coronavirus infection of man.

Authors:  K A Callow; H F Parry; M Sergeant; D A Tyrrell
Journal:  Epidemiol Infect       Date:  1990-10       Impact factor: 2.451

3.  The time course of the humoral immune response to rhinovirus infection.

Authors:  W S Barclay; W al-Nakib; P G Higgins; D A Tyrrell
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

4.  Trends and Intensity of Rhinovirus Invasions in Kilifi, Coastal Kenya, Over a 12-Year Period, 2007-2018.

Authors:  John Mwita Morobe; Everlyn Kamau; Nickson Murunga; Winfred Gatua; Martha M Luka; Clement Lewa; Robinson Cheruiyot; Martin Mutunga; Calleb Odundo; D James Nokes; Charles N Agoti
Journal:  Open Forum Infect Dis       Date:  2021-11-16       Impact factor: 3.835

5.  Evaluation of a new enzyme-linked immunosorbent assay (ELISA) in the diagnosis of rhinovirus infection.

Authors:  W al-Nakib; C J Dearden; D A Tyrrell
Journal:  J Med Virol       Date:  1989-12       Impact factor: 2.327

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.